HeartSciences (NASDAQ:HSCS) Issues Earnings Results

HeartSciences (NASDAQ:HSCS) issued its earnings results on Monday. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.05, Zacks reports.

HeartSciences Trading Down 3.1%

Shares of NASDAQ:HSCS opened at $2.47 on Tuesday. HeartSciences has a 12 month low of $2.01 and a 12 month high of $6.47. The company has a market capitalization of $6.55 million, a price-to-earnings ratio of -0.30 and a beta of 2.57. The firm’s 50-day moving average is $2.98 and its 200 day moving average is $3.42.

Analyst Ratings Changes

A number of research analysts have recently weighed in on HSCS shares. Ascendiant Capital Markets cut their price objective on HeartSciences from $15.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. Wall Street Zen raised HeartSciences from a “sell” rating to a “hold” rating in a research note on Friday, October 3rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a research note on Monday, December 8th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, HeartSciences currently has an average rating of “Hold” and a consensus price target of $10.50.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in HeartSciences stock. Geode Capital Management LLC purchased a new position in HeartSciences Inc. (NASDAQ:HSCS) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned 0.51% of HeartSciences as of its most recent filing with the Securities and Exchange Commission (SEC). 17.24% of the stock is currently owned by institutional investors.

About HeartSciences

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.